Alteogen Inc.
196170
株式のランク
#1732
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
株価
$174.43
時価総額
$12.14B
変化（1日）
5.32%
変化（1年）
-44.70%
国
KR
取引 Alteogen Inc. (196170)
カテゴリー
Healthcare
Alteogen Inc.（196170）の株価履歴
終値の最高値: $166.16 （2026-10-01）
終値の最安値: $3.00 （2014-12-01）
終値の最安値: $3.00 （2014-12-01）
Alteogen Inc. の株価履歴（2014 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2026 (TTM) | -17.41% |
| 2025 | 48.44% |
| 2024 | 250.17% |
| 2023 | 104.34% |
| 2022 | -46.14% |
| 2021 | -36.60% |
| 2020 | 507.66% |
| 2019 | 109.12% |
| 2018 | 18.35% |
| 2017 | 66.19% |
| 2016 | -22.35% |
| 2015 | 47.98% |
| 2014 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $535.90 | 25.67% |
US
|
|
| $184.77 | 588.14% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $881.33 | 8.25% |
NL
|
